JP2025500944A - ＥＧＦＲ－ｃＭＥＴ標的化合物及びその使用 - Google Patents
ＥＧＦＲ－ｃＭＥＴ標的化合物及びその使用 Download PDFInfo
- Publication number
- JP2025500944A JP2025500944A JP2024537033A JP2024537033A JP2025500944A JP 2025500944 A JP2025500944 A JP 2025500944A JP 2024537033 A JP2024537033 A JP 2024537033A JP 2024537033 A JP2024537033 A JP 2024537033A JP 2025500944 A JP2025500944 A JP 2025500944A
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- antigen
- acid sequence
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163291910P | 2021-12-20 | 2021-12-20 | |
| US63/291,910 | 2021-12-20 | ||
| PCT/US2022/082021 WO2023122588A2 (en) | 2021-12-20 | 2022-12-20 | Egfr-cmet–targeted compounds and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500944A true JP2025500944A (ja) | 2025-01-15 |
| JP2025500944A5 JP2025500944A5 (enExample) | 2025-12-24 |
Family
ID=86903719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537033A Pending JP2025500944A (ja) | 2021-12-20 | 2022-12-20 | ＥＧＦＲ－ｃＭＥＴ標的化合物及びその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20250121104A1 (enExample) |
| EP (1) | EP4452954A2 (enExample) |
| JP (1) | JP2025500944A (enExample) |
| KR (1) | KR20240125970A (enExample) |
| CN (1) | CN118765273A (enExample) |
| AR (1) | AR128052A1 (enExample) |
| AU (1) | AU2022419564A1 (enExample) |
| CA (1) | CA3244030A1 (enExample) |
| CL (1) | CL2024001832A1 (enExample) |
| CO (1) | CO2024008733A2 (enExample) |
| CR (1) | CR20240254A (enExample) |
| IL (1) | IL313333A (enExample) |
| MX (1) | MX2024007596A (enExample) |
| TW (1) | TW202333799A (enExample) |
| WO (1) | WO2023122588A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3265502A1 (en) * | 2022-08-22 | 2024-02-29 | Abdera Therapeutics Inc. | DOTA ANTIBODY CONJUGATES VHH |
| EP4763865A1 (en) * | 2023-08-14 | 2026-06-24 | Minghui Pharmaceutical (Hangzhou) Limited | Anti-c-met nanobody and use thereof |
| WO2025148868A1 (zh) | 2024-01-08 | 2025-07-17 | 泰励生物科技（上海）有限公司 | 一种抗体偶联药物及其用途 |
| CN118085101A (zh) * | 2024-03-01 | 2024-05-28 | 烟台蓝纳成生物技术有限公司 | 一种二价双特异性抗体、抗体偶联核素药物及其应用 |
| WO2025195500A1 (zh) * | 2024-03-22 | 2025-09-25 | 康源博创生物科技(北京)有限公司 | 一种多肽及其用于构建包含共同轻链的双特异性抗体中的应用 |
| WO2026149557A1 (zh) * | 2025-01-10 | 2026-07-16 | 正大天晴药业集团股份有限公司 | 新型亲水性连接体及其药物连接体、蛋白质偶联药物、药物组合物和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3823988A1 (en) * | 2018-07-19 | 2021-05-26 | Eli Lilly and Company | Bispecific antibodies targeting immune checkpoints |
| WO2021133036A1 (ko) * | 2019-12-23 | 2021-07-01 | 주식회사 엘지화학 | 항-lilrb1 항체 및 그의 용도 |
| KR20220157464A (ko) * | 2020-03-23 | 2022-11-29 | 퓨전 파마슈티칼즈 인크. | Fgfr3-표적화된 방사선면역접합체 및 그의 용도 |
| WO2021207086A1 (en) * | 2020-04-06 | 2021-10-14 | Fusion Pharmaceuticals Inc. | Tem-1-targeted radioimmunoconjugates and uses thereof |
-
2022
- 2022-12-20 JP JP2024537033A patent/JP2025500944A/ja active Pending
- 2022-12-20 AU AU2022419564A patent/AU2022419564A1/en active Pending
- 2022-12-20 WO PCT/US2022/082021 patent/WO2023122588A2/en not_active Ceased
- 2022-12-20 IL IL313333A patent/IL313333A/en unknown
- 2022-12-20 CN CN202280092041.0A patent/CN118765273A/zh active Pending
- 2022-12-20 EP EP22912656.0A patent/EP4452954A2/en active Pending
- 2022-12-20 US US18/721,647 patent/US20250121104A1/en active Pending
- 2022-12-20 CA CA3244030A patent/CA3244030A1/en active Pending
- 2022-12-20 CR CR20240254A patent/CR20240254A/es unknown
- 2022-12-20 MX MX2024007596A patent/MX2024007596A/es unknown
- 2022-12-20 TW TW111149059A patent/TW202333799A/zh unknown
- 2022-12-20 KR KR1020247024103A patent/KR20240125970A/ko active Pending
- 2022-12-21 AR ARP220103534A patent/AR128052A1/es unknown
-
2024
- 2024-06-18 CL CL2024001832A patent/CL2024001832A1/es unknown
- 2024-06-28 CO CONC2024/0008733A patent/CO2024008733A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240125970A (ko) | 2024-08-20 |
| CA3244030A1 (en) | 2023-06-29 |
| CN118765273A (zh) | 2024-10-11 |
| MX2024007596A (es) | 2024-07-09 |
| US20250121104A1 (en) | 2025-04-17 |
| TW202333799A (zh) | 2023-09-01 |
| CL2024001832A1 (es) | 2024-11-22 |
| EP4452954A2 (en) | 2024-10-30 |
| AR128052A1 (es) | 2024-03-20 |
| AU2022419564A1 (en) | 2024-07-04 |
| WO2023122588A3 (en) | 2023-09-21 |
| IL313333A (en) | 2024-08-01 |
| CO2024008733A2 (es) | 2024-07-29 |
| CR20240254A (es) | 2025-01-13 |
| WO2023122588A2 (en) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250121104A1 (en) | Egfr-cmet-targeted compounds and uses thereof | |
| CN120225566A (zh) | Dll3结合分子及其用途 | |
| JP2025529894A (ja) | Ｖｈｈ抗体ｄｏｔａコンジュゲート | |
| US20240139353A1 (en) | Methods of treating cancer | |
| EP4423137A1 (en) | Claudin 18.2-targeted compounds and uses thereof | |
| TW202204336A (zh) | 標靶tem-1之放射免疫結合物及其用途 | |
| JP2024535444A (ja) | ＥＧＦＲｖＩＩＩを標的とした化合物およびその使用 | |
| JP2023518818A (ja) | Ｆｇｆｒ３に標的化されたラジオイムノコンジュゲートおよびその使用 | |
| US20240350682A1 (en) | Steap2-targeted compounds and use thereof | |
| TW202508645A (zh) | 放射性藥物用於癌症治療之用途 | |
| WO2024216389A9 (en) | Claudin 18.2-targeted compounds and uses thereof | |
| CA3237041A1 (en) | Methods of treating cancer | |
| HK40084697A (en) | Fgfr3-targeted radioimmunoconjugates and uses thereof | |
| TW202600607A (zh) | Ｄｄｌ３結合免疫接合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251216 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251216 |